Combination of Tocilizumab and Steroids to Improve Mortality in Patients with Severe COVID-19 Infection: A Spanish, Mult
- PDF / 918,190 Bytes
- 16 Pages / 595.276 x 790.866 pts Page_size
- 49 Downloads / 140 Views
ORIGINAL RESEARCH
Combination of Tocilizumab and Steroids to Improve Mortality in Patients with Severe COVID-19 Infection: A Spanish, Multicenter, Cohort Study Bele´n Ruiz-Antora´n
. Ara´nzazu Sancho-Lo´pez . Ferra´n Torres . Vı´ctor Moreno-Torres .
Itziar de Pablo-Lo´pez . Paulina Garcı´a-Lo´pez . Francisco Abad-Santos . Clara M. Rosso-Ferna´ndez . Ana Aldea-Perona . Eva Montane´ . Ruth M. Aparicio-Herna´ndez . Roser Llop-Rius . Consuelo Pedro´s . Paloma Gijo´n . Carolina Herna´ndez-Carballo . Marı´a J. Pedrosa-Martı´nez . Consuelo Rodrı´guez-Jime´nez . Guillermo Prada-Ramallal . Lourdes Cabrera-Garcı´a . Josefa A. Aguilar-Garcı´a . Rocı´o Sanjuan-Jimenez . Evelyn I. Ortiz-Barraza . Enrique Sa´nchez-Chica . Ana Ferna´ndez-Cruz on behalf of the TOCICOV-study group
Received: October 7, 2020 / Accepted: November 16, 2020 Ó The Author(s) 2020
ABSTRACT Background: We aimed to determine the impact of tocilizumab use on severe COVID-19 (coronavirus disease 19) pneumonia mortality. Bele´n Ruiz-Antora´n and Ara´nzazu Sancho-Lo´pez contributed equally to this work.
Electronic supplementary material The online version of this article (https://doi.org/10.1007/s40121020-00373-8) contains supplementary material, which is available to authorized users. B. Ruiz-Antora´n (&) A. Sancho-Lo´pez Clinical Pharmacology Department, Hospital Universitario Puerta de Hierro-Majadahonda, Instituto de Investigacio´n Sanitaria Puerta de Hierro-Segovia de Arana, Madrid, Spain e-mail: [email protected] F. Torres Medical Statistics Core Facility, August Pi i Sunyer Biomedical Research Institute, Hospital Clinic, Barcelona, Spain F. Torres Biostatistics Unit, Faculty of Medicine, Autonomous University of Barcelona, Barcelona, Spain V. Moreno-Torres E. Sa´nchez-Chica Internal Medicine Department, Hospital Universitario Puerta de Hierro-Majadahonda, Instituto de Investigacio´n Sanitaria Puerta de Hierro-Segovia de Arana, Madrid, Spain
Methods: We performed a multicentre retrospective cohort study in 18 tertiary hospitals in Spain from March to April 2020. Consecutive patients admitted with severe COVID-19 treated with tocilizumab were compared to patients not treated with tocilizumab, adjusting by inverse probability of the treatment weights (IPTW). Tocilizumab’s effect in patients receiving steroids during the 48 h following inclusion was analysed. Results: During the study period, 506 patients with severe COVID-19 fulfilled the inclusion I. de Pablo-Lo´pez Clinical Pharmacology Unit, Hospital Universitario Ramo´n y Cajal (IRYCIS), Madrid, Spain P. Garcı´a-Lo´pez Pneumology Department, Hospital Universitario Torrecardenas, Almerı´a, Spain F. Abad-Santos Clinical Pharmacology Department, Hospital Universitario de la Princesa, Instituto Teo´filo Hernando, Faculty of Medicine, Universidad Auto´noma de Madrid (UAM), Instituto de Investigacio´n Sanitaria la Princesa (IP), Madrid, Spain C. M. Rosso-Ferna´ndez Unit of Clinical Pharmacology, Unit of Clinical Investigation and Clinical Trials, Hospital Universitario Virgen del Rocı´o, Sevill
Data Loading...
